18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression-free Survival (PFS)Primary· Through completion of follow-up (median follow-up was 6.61 months)
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.
Progression - at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
Appearance of one or more new lesions and/or unequivocal progression of existing no
Group
Value
95% CI
Pacritinib
1.91
1.81 – 8.75
Toxicity Profile and Tolerability as Measured by Reportable Adverse EventsSecondary· Up to 28 days following last day of study treatment
* The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.
* Reportable adverse events will be tracked for 28 days following the last day of study treatment. For the purposes of this protocol, reportable adverse events are events that are greater than or equal to grade 2 and are considered possibly, probably, or definitely related to study treatment.
Diarrhea
Group
Value
95% CI
Pacritinib
1
Edema limbs
Group
Value
95% CI
Pacritinib
1
Edema face
Group
Value
95% CI
Pacritinib
1
Fatigue
Group
Value
95% CI
Pacritinib
1
Localized edema
Group
Value
95% CI
Pacritinib
1
Blood bilirubin increased
Group
Value
95% CI
Pacritinib
1
Dyspnea
Group
Value
95% CI
Pacritinib
1
Rash maculopapular
Group
Value
95% CI
Pacritinib
1
Overall Response Rate (ORR)Secondary· Through completion of follow-up (median follow-up was 6.61 months)
* The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
* Using RECIST 1.1
* The follow-up time was calculated from the start of treatment until death or on the final collection date of data on 10/27/2016.
Group
Value
95% CI
Pacritinib
0
Pacritinib
0
Pacritinib
1
Pacritinib
6
Time to Progression (TTP)Secondary· Through completion of follow-up (median follow-up was 6.61 months)
Group
Value
95% CI
Pacritinib
1.73
± 0.26
Overall Survival (OS)Secondary· Through completion of follow-up (median follow-up was 6.61 months)
-The follow-up time for OS was calculated from the start of treatment until death or on the final collection date of data on 10/27/2016.
Group
Value
95% CI
Pacritinib
6.61
2.79 – 9.34
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The investigators propose to assess the efficacy, progression-free survival, and adverse events of pacritinib in patients with refractory colorectal cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym
· Phase 1
· recruiting
NCT07447817 — Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
· Phase 2
· not yet recruiting
NCT07148947 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant
· Phase 2
· recruiting
NCT07226713 — Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatmen
· Phase 2
· not yet recruiting
NCT06986174 — A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemi
· Phase 2
· recruiting
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
· Phase 1, PHASE2
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes
· recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes
· recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
· Phase 2
· not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer
· Phase 2
· not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
· Phase 1
· not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients
· not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial)
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 1 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02277093.